Applied Therapeutics Stock Analysis
| APLT Stock | USD 0.10 0.00 0.00% |
IPO Date 14th of May 2019 | 200 Day MA 0.4626 | 50 Day MA 0.1461 | Beta 2.084 |
Applied Therapeutics holds a debt-to-equity ratio of 0.139. At this time, Applied Therapeutics' Long Term Debt is comparatively stable compared to the past year. Short and Long Term Debt is likely to gain to about 512.4 K in 2026, whereas Interest Debt Per Share is likely to drop 0.02 in 2026. Applied Therapeutics' financial risk is the risk to Applied Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Applied Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Applied Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Applied Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Applied Therapeutics' stakeholders.
For many companies, including Applied Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Applied Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Applied Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 7.7151 | Enterprise Value Ebitda (9.71) | Price Sales 14.863 | Shares Float 119.8 M | Wall Street Target Price 0.25 |
Given that Applied Therapeutics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Applied Therapeutics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Applied Therapeutics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Applied Therapeutics is said to be less leveraged. If creditors hold a majority of Applied Therapeutics' assets, the Company is said to be highly leveraged.
At this time, Applied Therapeutics' Total Stockholder Equity is comparatively stable compared to the past year. Common Stock Total Equity is likely to gain to 2,415 in 2026, whereas Issuance Of Capital Stock is likely to drop slightly above 76.3 M in 2026. . At this time, Applied Therapeutics' Price To Sales Ratio is comparatively stable compared to the past year. Price Book Value Ratio is likely to gain to 1.98 in 2026, whereas Price To Free Cash Flows Ratio is likely to drop (1.34) in 2026. Applied Therapeutics is undervalued with Real Value of 0.14 and Target Price of 0.25. The main objective of Applied Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Applied Therapeutics is worth, separate from its market price. There are two main types of Applied Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Applied Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Applied Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Applied Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Applied Stock Analysis Notes
About 69.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.1. Applied Therapeutics had not issued any dividends in recent years. Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. Applied Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 30 people. For more info on Applied Therapeutics please contact the company at 212 220 9226 or go to https://www.appliedtherapeutics.com.Applied Therapeutics Investment Alerts
| Applied Therapeutics is not yet fully synchronised with the market data | |
| Applied Therapeutics generated a negative expected return over the last 90 days | |
| Applied Therapeutics has high historical volatility and very poor performance | |
| Applied Therapeutics has some characteristics of a very speculative penny stock | |
| Applied Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 455 K. Net Loss for the year was (105.62 M) with loss before overhead, payroll, taxes, and interest of (38.06 M). | |
| Applied Therapeutics currently holds about 67.72 M in cash with (84.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Applied Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 69.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Disposition of 23941 shares by Lerner Teena of Applied Therapeutics at 4.7 subject to Rule 16b-3 |
Applied Largest EPS Surprises
Earnings surprises can significantly impact Applied Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-08-13 | 2025-06-30 | -0.17 | -0.15 | 0.02 | 11 | ||
2022-11-09 | 2022-09-30 | -0.48 | -0.4 | 0.08 | 16 | ||
2024-03-06 | 2023-12-31 | -0.23 | -0.34 | -0.11 | 47 |
Applied Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2025-06-30 | 1.9 M | Qube Research & Technologies | 2025-06-30 | 1.8 M | Marshall Wace Asset Management Ltd | 2025-06-30 | 1.5 M | Adage Capital Partners Gp Llc | 2025-06-30 | 1.2 M | Geode Capital Management, Llc | 2025-06-30 | 968.5 K | Ubs Group Ag | 2025-06-30 | 830.6 K | Goldman Sachs Group Inc | 2025-06-30 | 730.7 K | Deutsche Bank Ag | 2025-06-30 | 622.2 K | Two Sigma Investments Llc | 2025-06-30 | 594.5 K | T. Rowe Price Investment Management,inc. | 2025-06-30 | 18.7 M | Vestal Point Capital Lp | 2025-06-30 | 11.5 M |
Applied Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 14.86 M.Applied Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.40) | (1.47) | |
| Return On Capital Employed | (2.02) | (2.12) | |
| Return On Assets | (1.40) | (1.47) | |
| Return On Equity | (2.13) | (2.24) |
Management Efficiency
Applied Therapeutics has return on total asset (ROA) of (0.8835) % which means that it has lost $0.8835 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.8047) %, meaning that it created substantial loss on money invested by shareholders. Applied Therapeutics' management efficiency ratios could be used to measure how well Applied Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.47 in 2026. Return On Capital Employed is likely to drop to -2.12 in 2026. Change To Liabilities is likely to gain to about 10.7 M in 2026, whereas Total Current Liabilities is likely to drop slightly above 27.4 M in 2026.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.47 | 0.45 | |
| Tangible Book Value Per Share | 0.47 | 0.45 | |
| Enterprise Value Over EBITDA | (0.47) | (0.45) | |
| Price Book Value Ratio | 1.89 | 1.98 | |
| Enterprise Value Multiple | (0.47) | (0.45) | |
| Price Fair Value | 1.89 | 1.98 | |
| Enterprise Value | 203.9 M | 333.4 M |
The decision-making processes within Applied Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Applied Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Applied Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Applied Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Applied Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Applied Therapeutics Outstanding Bonds
Applied Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Applied Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Applied bonds can be classified according to their maturity, which is the date when Applied Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| APPLIED MATLS INC Corp BondUS038222AG04 | View | |
| APPLIED MATERIALS INC Corp BondUS038222AN54 | View | |
| APPLIED MATERIALS INC Corp BondUS038222AP03 | View | |
| APPLIED MATLS INC Corp BondUS038222AK16 | View | |
| APPLIED MATLS INC Corp BondUS038222AL98 | View | |
| APPLIED MATLS INC Corp BondUS038222AM71 | View |
Applied Therapeutics Predictive Daily Indicators
Applied Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Applied Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Applied Therapeutics Bond Ratings
Applied Therapeutics financial ratings play a critical role in determining how much Applied Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Applied Therapeutics' borrowing costs.| Piotroski F Score | 2 | Frail | View |
| Beneish M Score | (4.40) | Unlikely Manipulator | View |
Applied Therapeutics Debt to Cash Allocation
Applied Therapeutics currently holds 2.79 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. Applied Therapeutics has a current ratio of 1.46, which is within standard range for the sector. Note, when we think about Applied Therapeutics' use of debt, we should always consider it together with its cash and equity.Applied Therapeutics Total Assets Over Time
Applied Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Applied Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Applied Therapeutics Debt Ratio | 3.5 |
Applied Therapeutics Corporate Bonds Issued
Applied Net Debt
Net Debt |
|
About Applied Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Applied Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Applied shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Applied Therapeutics. By using and applying Applied Stock analysis, traders can create a robust methodology for identifying Applied entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (266.96) | (280.31) | |
| Operating Profit Margin | (263.61) | (250.43) | |
| Net Loss | (266.96) | (280.31) | |
| Gross Profit Margin | (122.05) | (115.95) |
Current Applied Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Applied analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Applied analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 0.25 | Buy | 4 | Odds |
Most Applied analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Applied stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Applied Therapeutics, talking to its executives and customers, or listening to Applied conference calls.
Applied Stock Analysis Indicators
Applied Therapeutics stock analysis indicators help investors evaluate how Applied Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Applied Therapeutics shares will generate the highest return on investment. By understating and applying Applied Therapeutics stock analysis, traders can identify Applied Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 49.9 M | |
| Common Stock Shares Outstanding | 139.5 M | |
| Total Stockholder Equity | 57 M | |
| Property Plant And Equipment Net | 2.8 M | |
| Cash And Short Term Investments | 79.4 M | |
| Cash | 79.4 M | |
| Accounts Payable | 4.4 M | |
| Net Debt | -76.6 M | |
| 50 Day M A | 0.1461 | |
| Total Current Liabilities | 27.3 M | |
| Other Operating Expenses | 104.8 M | |
| Non Current Assets Total | 3 M | |
| Non Currrent Assets Other | 253 K | |
| Stock Based Compensation | 13.5 M |
Additional Tools for Applied Stock Analysis
When running Applied Therapeutics' price analysis, check to measure Applied Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Applied Therapeutics is operating at the current time. Most of Applied Therapeutics' value examination focuses on studying past and present price action to predict the probability of Applied Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Applied Therapeutics' price. Additionally, you may evaluate how the addition of Applied Therapeutics to your portfolios can decrease your overall portfolio volatility.